Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

• Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule

• Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk

$5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross margins

Direct-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocation

Early U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy

CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a commercial and financial update on Liv18, its clinically validated liver health supplement, as the Company accelerates its expansion across the United States.

The Company has successfully completed Phase 1 execution for Liv18 (defined as product development, packaging, and initial commercial setup) ahead of schedule. Production is expected to commence in April 2026, with initial market rollout to follow shortly thereafter.

Liv18 will be manufactured in the United States at GMP-certified, FDA-registered, and UL-audited facilities, reflecting high standards of quality, safety, and regulatory compliance. This localized approach enhances supply chain efficiency, reduces complexity, mitigates tariff exposure, and supports scalable U.S. growth.

Based on planned investments in advertising, customer acquisition, and business development, along with early U.S. commercial traction from other Cosmos Health products, the Company expects Liv18 to generate over $5 million in annual revenue, with gross margins of approximately 75%, reflecting its premium positioning and direct-to-consumer focused go-to-market strategy.

Liv18 is expected to represent a meaningful incremental revenue stream and a high-margin contribution, supporting a significant uplift in overall profitability as the Company expands its U.S. operations.

The Company continues to prioritize the United States as a key strategic growth market and is making targeted investments to drive scalable growth.

Greg Siokas, CEO of Cosmos Health, stated: "The completion of Phase 1 execution for Liv18 is a significant milestone - and one that is ahead of schedule - as we prepare for its commercial rollout in the United States. We expect Liv18 to be a meaningful incremental revenue driver, with high margins expected to support a significant uplift in overall profitability. The U.S. is a key strategic priority for Cosmos Health, and we are actively investing to accelerate growth and enhance profitability."